# Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study

> **NCT06516484** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT06516484
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516484, "Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06516484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*